ARTICLE | Finance
Build-to-buy basket
GSK, Avalon Ventures double their build-to-buy portfolio to six start-ups
June 22, 2015 7:00 AM UTC
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC.
The newest cohort of companies includes Adrenergics Inc., CadheRx Therapeutics Inc. and Calporta Therapeutics Inc. ...